255 related articles for article (PubMed ID: 23902939)
1. Mechanisms that underlie μ-opioid receptor agonist-induced constipation: differential involvement of μ-opioid receptor sites and responsible regions.
Mori T; Shibasaki Y; Matsumoto K; Shibasaki M; Hasegawa M; Wang E; Masukawa D; Yoshizawa K; Horie S; Suzuki T
J Pharmacol Exp Ther; 2013 Oct; 347(1):91-9. PubMed ID: 23902939
[TBL] [Abstract][Full Text] [Related]
2. Involvement of supraspinal and peripheral naloxonazine-insensitive opioid receptor sites in the expression of μ-opioid receptor agonist-induced physical dependence.
Mori T; Komiya S; Uzawa N; Inoue K; Itoh T; Aoki S; Shibasaki M; Suzuki T
Eur J Pharmacol; 2013 Sep; 715(1-3):238-45. PubMed ID: 23707904
[TBL] [Abstract][Full Text] [Related]
3. Differences in the morphine-induced inhibition of small and large intestinal transit: Involvement of central and peripheral μ-opioid receptors in mice.
Matsumoto K; Umemoto H; Mori T; Akatsu R; Saito S; Tashima K; Shibasaki M; Kato S; Suzuki T; Horie S
Eur J Pharmacol; 2016 Jan; 771():220-8. PubMed ID: 26712376
[TBL] [Abstract][Full Text] [Related]
4. Involvement of mu-opioid receptors in antinociception and inhibition of gastrointestinal transit induced by 7-hydroxymitragynine, isolated from Thai herbal medicine Mitragyna speciosa.
Matsumoto K; Hatori Y; Murayama T; Tashima K; Wongseripipatana S; Misawa K; Kitajima M; Takayama H; Horie S
Eur J Pharmacol; 2006 Nov; 549(1-3):63-70. PubMed ID: 16978601
[TBL] [Abstract][Full Text] [Related]
5. Modulation of peripheral μ-opioid analgesia by σ1 receptors.
Sánchez-Fernández C; Montilla-García Á; González-Cano R; Nieto FR; Romero L; Artacho-Cordón A; Montes R; Fernández-Pastor B; Merlos M; Baeyens JM; Entrena JM; Cobos EJ
J Pharmacol Exp Ther; 2014 Jan; 348(1):32-45. PubMed ID: 24155346
[TBL] [Abstract][Full Text] [Related]
6. Functional effects of systemically administered agonists and antagonists of mu, delta, and kappa opioid receptor subtypes on body temperature in mice.
Baker AK; Meert TF
J Pharmacol Exp Ther; 2002 Sep; 302(3):1253-64. PubMed ID: 12183687
[TBL] [Abstract][Full Text] [Related]
7. Antidiarrheal properties of supraspinal mu and delta and peripheral mu, delta and kappa opioid receptors: inhibition of diarrhea without constipation.
Shook JE; Lemcke PK; Gehrig CA; Hruby VJ; Burks TF
J Pharmacol Exp Ther; 1989 Apr; 249(1):83-90. PubMed ID: 2540324
[TBL] [Abstract][Full Text] [Related]
8. Involvement of peripheral mu opioid receptors in scratching behavior in mice.
Yamamoto A; Sugimoto Y
Eur J Pharmacol; 2010 Dec; 649(1-3):336-41. PubMed ID: 20863827
[TBL] [Abstract][Full Text] [Related]
9. Dissociation of opioid antinociception and central gastrointestinal propulsion in the mouse: studies with naloxonazine.
Heyman JS; Williams CL; Burks TF; Mosberg HI; Porreca F
J Pharmacol Exp Ther; 1988 Apr; 245(1):238-43. PubMed ID: 2834537
[TBL] [Abstract][Full Text] [Related]
10. Antibodies and antisense oligodeoxynucleotides to mu-opioid receptors, selectively block the effects of mu-opioid agonists on intestinal transit and permeability in mice.
Pol O; Valle L; Sánchez-Blázquez P; Garzón J; Puig MM
Br J Pharmacol; 1999 May; 127(2):397-404. PubMed ID: 10385239
[TBL] [Abstract][Full Text] [Related]
11. In vivo pharmacological characterization of SoRI 9409, a nonpeptidic opioid mu-agonist/delta-antagonist that produces limited antinociceptive tolerance and attenuates morphine physical dependence.
Wells JL; Bartlett JL; Ananthan S; Bilsky EJ
J Pharmacol Exp Ther; 2001 May; 297(2):597-605. PubMed ID: 11303048
[TBL] [Abstract][Full Text] [Related]
12. Involvement of mu1-opioid receptor on oxycodone-induced antinociception in diabetic mice.
Nozaki C; Kamei J
Eur J Pharmacol; 2007 Apr; 560(2-3):160-2. PubMed ID: 17292346
[TBL] [Abstract][Full Text] [Related]
13. Effect of diabetes on the morphine-induced inhibition of gastrointestinal transit.
Kamei J; Ohsawa M; Misawa M; Nagase H; Kasuya Y
Nihon Shinkei Seishin Yakurigaku Zasshi; 1995 Apr; 15(2):165-9. PubMed ID: 7796321
[TBL] [Abstract][Full Text] [Related]
14. Interaction of mu-opioid receptor agonists and antagonists with the analgesic effect of buprenorphine in mice.
Kögel B; Christoph T; Strassburger W; Friderichs E
Eur J Pain; 2005 Oct; 9(5):599-611. PubMed ID: 16139189
[TBL] [Abstract][Full Text] [Related]
15. Effects of naloxone and D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice.
Bilsky EJ; Bernstein RN; Wang Z; Sadée W; Porreca F
J Pharmacol Exp Ther; 1996 Apr; 277(1):484-90. PubMed ID: 8613958
[TBL] [Abstract][Full Text] [Related]
16. Effects of mu, kappa or delta opioids administered by pellet or pump on oral Salmonella infection and gastrointestinal transit.
Feng P; Rahim RT; Cowan A; Liu-Chen LY; Peng X; Gaughan J; Meissler JJ; Adler MW; Eisenstein TK
Eur J Pharmacol; 2006 Mar; 534(1-3):250-7. PubMed ID: 16513108
[TBL] [Abstract][Full Text] [Related]
17. Opioid agonist and antagonist treatment differentially regulates immunoreactive mu-opioid receptors and dynamin-2 in vivo.
Yoburn BC; Purohit V; Patel K; Zhang Q
Eur J Pharmacol; 2004 Sep; 498(1-3):87-96. PubMed ID: 15363980
[TBL] [Abstract][Full Text] [Related]
18. Preclinical studies of opioids and opioid antagonists on gastrointestinal function.
Greenwood-Van Meerveld B; Gardner CJ; Little PJ; Hicks GA; Dehaven-Hudkins DL
Neurogastroenterol Motil; 2004 Oct; 16 Suppl 2():46-53. PubMed ID: 15357851
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic Profile of Naloxegol, a Peripherally Acting
Floettmann E; Bui K; Sostek M; Payza K; Eldon M
J Pharmacol Exp Ther; 2017 May; 361(2):280-291. PubMed ID: 28336575
[TBL] [Abstract][Full Text] [Related]
20. Opioid-induced constipation: challenges and therapeutic opportunities.
Camilleri M
Am J Gastroenterol; 2011 May; 106(5):835-42; quiz 843. PubMed ID: 21343919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
